Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymostimulin is a **standardized peptide fraction** derived from bovine thymus glands, prepared by extracting and purifying low-molecular-weight thymic peptides while removing higher-molecular-weight proteins and cell components[1][3]. It contains immunomodulatory peptides such as thymosin-α1 and thymic humoral factor. Its mechanism is believed to involve stimulation of proinflammatory cytokines, enhancement of T-cell proliferation and differentiation, and increased antigen expression on tumor cells, resulting in cytotoxic immune responses, particularly against tumor cells[1][3]. Thymostimulin was primarily investigated for use in advanced **hepatocellular carcinoma** (HCC) and other immunodeficiency or cancer-associated conditions. It was developed as a **licensed immunomodulating agent**, with phase II and phase III clinical trials performed in HCC and advanced AIDS-related complex[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thymostimulin.